Cargando…
Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 tre...
Autores principales: | Nakamura, Hideta, Miyagi, Kazuya, Otsuki, Mariko, Higure, Yuuri, Nishiyama, Naoya, Kinjo, Takeshi, Nakamatsu, Masashi, Haranaga, Shusaku, Tateyama, Masao, Fujita, Jiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725631/ https://www.ncbi.nlm.nih.gov/pubmed/32963155 http://dx.doi.org/10.2169/internalmedicine.5244-20 |
Ejemplares similares
-
Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series
por: Nakamura, Hideta, et al.
Publicado: (2020) -
Case Report: Iliopsoas Hematoma during the Clinical Course of Severe COVID-19 in Two Male Patients
por: Nakamura, Hideta, et al.
Publicado: (2021) -
Case Report: Ischemic Enterocolitis Associated with Coronavirus Disease 2019: Two Case Reports and a Review of the Literature
por: Kinjo, Takeshi, et al.
Publicado: (2021) -
Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19
por: Nakamura, Hideta, et al.
Publicado: (2020) -
Evaluation of Anyplex™ II RV16 and RB5 real-time RT-PCR compared to Seeplex(®) RV15 OneStep ACE and PneumoBacter ACE for the simultaneous detection of upper respiratory pathogens
por: Parrott, Gretchen, et al.
Publicado: (2017)